BlackRock Institutional Trust’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

BlackRock Institutional Trust’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$17.6M	Buy	221,266 +15,351	+7%	+$1.12M	﹤0.01%	2065
2016 Q3	$14.4M	Sell	205,915 -31,795	-13%	-$1.76M	﹤0.01%	2107
2016 Q2	$9.22M	Buy	237,710 +39	+0%	+$1.62K	﹤0.01%	2338
2016 Q1	$9.63M	Buy	237,671 +26,882	+13%	+$1.71M	﹤0.01%	2281
2015 Q4	$18.7M	Sell	210,789 -24,844	-11%	-$1.96M	﹤0.01%	1918
2015 Q3	$17.4M	Buy	235,633 +53,614	+29%	+$4.46M	﹤0.01%	1931
2015 Q2	$14.7M	Buy	182,019 +149,486	+459%	+$9.74M	﹤0.01%	2134
2015 Q1	$1.36M	Buy	+32,533	New	+$923K	﹤0.01%	3257
2014 Q2	–	Sell	-28,510	Closed	-$364K	–	4049
2014 Q1	$364K	Buy	+28,510	New	+$387K	﹤0.01%	3622

Other funds holding EGRX

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

BlackRock Institutional Trust's EGRX Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Eagle Pharmaceuticals, Inc. (EGRX) stake by 7.5% in Q4 2016, buying an estimated $1.12M and bringing the position to 221,266 shares worth $17.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2065.

BlackRock Institutional Trust first reported a position in EGRX in Q1 2014 and has held it in 9 quarters since. The position peaked at $18.7M in Q4 2015. 149 funds tracked by Wall St. Rank hold EGRX as of Q4 2016.

BlackRock Institutional Trust held 221,266 shares of Eagle Pharmaceuticals, Inc. worth $17.6M as of Q4 2016.
BlackRock Institutional Trust bought 15,351 Eagle Pharmaceuticals, Inc. shares in Q4 2016, an estimated $1.12M.
Eagle Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2065 holding.
BlackRock Institutional Trust first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and has held it in 9 quarters since.
BlackRock Institutional Trust's Eagle Pharmaceuticals, Inc. position peaked at $18.7M in Q4 2015.
149 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.